Analy­sis shows The Med­i­cines Com­pa­ny/Al­ny­lam drug in­clisir­an safe for re­nal­ly-im­paired pa­tients

6 years ago
R&D

5 cash-hun­gry biotechs crowd in­to Nas­daq in search of a $600M-plus wind­fall

6 years ago
Financing

Fac­tor VI­II lev­els con­tin­ue to drop in Bio­Marin’s 3-year up­date on he­mo­phil­ia A gene ther­a­py — but wait...

6 years ago
R&D

Brad Lon­car­'s AS­CO19 pre­view: 5 big ideas to watch for at the ul­ti­mate can­cer show of the year

6 years ago
R&D
Biotech Voices

FDA hits the red light on piv­otal tri­als at Newron, de­mand­ing new stud­ies af­ter rais­ing safe­ty con­cerns

6 years ago
R&D
FDA+

Make that 2 prospec­tive block­buster ap­provals in 1 day for No­var­tis as FDA OKs tar­get­ed can­cer ther­a­py

6 years ago
R&D

No­var­tis rolls out its next big drug at a record-set­ting price of $2.12M — let the gene ther­a­py pric­ing de­bate ...

6 years ago
R&D
Cell/Gene Tx

Akre­via scoops ex-Ar­sa­nis chief René Rus­so as CEO; Scott Got­tlieb jumps back in­to in­dus­try; Seat­tle Ge­net­ics raids ...

6 years ago
Peer Review

Project Snow White: In­ter­nal probe re­veals for­mer MiMedx C-suite spied on em­ploy­ees, lied to reg­u­la­tors and mis­led ...

6 years ago
People
Pharma

Ideaya wraps $50M IPO to fu­el clin­i­cal dri­ve on syn­thet­ic lethal­i­ty

6 years ago
Financing

Life sci­ences fund rais­es €118M for its next round of bets; Gilead scraps Alpine al­liance

6 years ago
News Briefing

Sen­ate bill to cut health costs, tar­gets FDA tweaks

6 years ago
Pharma

Trump ad­min­is­tra­tion preps ex­ec­u­tive or­der on price trans­paren­cy as law­mak­ers con­verge — WSJ

6 years ago
Pharma

Novo­cure bags mesothe­lioma nod for elec­tric fields can­cer ther­a­py with some lim­i­ta­tions

6 years ago
Pharma

A new in­ter­leukin tar­get for NASH spawns Sin­ga­pore­an biotech steered by well known play­ers

6 years ago
Startups
Discovery

Ed Kaye is tak­ing his fledg­ling biotech to Wall Street, look­ing for a new in­jec­tion of cash

6 years ago
Financing
Startups

Sobered by mount­ing costs, Dy­navax looks to un­load I/O, slash jobs and cir­cle wag­ons around Hep­lisav

6 years ago
People
R&D

Dai­ichi Sankyo re­port­ed­ly sell­ing OTC unit for $900M in piv­ot to on­col­o­gy — but com­pa­ny says it's 'in­cor­rec­t'

6 years ago
Pharma

San­thera en­ters li­cense agree­ment with Chiesi Group; Tonix's co­caine in­tox­i­ca­tion drug, Io­vance's cer­vi­cal can­cer ...

6 years ago
News Briefing

Tread­ing on Nas­daq turf, NYSE cuts list­ing fees to woo biotech

6 years ago
Financing
R&D

In a change of plans, Nek­tar spins out its opi­oid in­to a new biotech sub­sidiary as FDA PDU­FA date looms

6 years ago
Pharma

In a re­mote Ver­mont ski town, 3 ex­ecs raised $93M for a stem cell re­search cam­pus. Pros­e­cu­tors say it was all just a ...

6 years ago
Pharma

Sarep­ta's Ex­ondys 51 is not cost-ef­fec­tive, nor par­tic­u­lar­ly ben­e­fi­cial for DMD pa­tients — ICER

6 years ago
R&D
Pharma

Bi­cy­cle rais­es $61M in down­sized IPO, join­ing fel­low biotechs on Nas­daq who have hauled in $1.6B col­lec­tive­ly

6 years ago
Financing
First page Previous page 931932933934935936937 Next page Last page
A service from the Financial Times